CLLS   $1.94  -7.62% Market Closed

Cellectis SA
Last Events:

2023-08-09 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2023-08-09 Trend Power changed from medium strength to slow.

2023-08-06 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-06 Signal in RSI changed from bearish to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from slow to medium strength.

2023-08-05 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-05 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-04 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.


Current temperature: 15.71
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 8
Target Price Mean 7.00
Mean unverified/preliminary 7.00 / 7.00
Target Price Low / High 3.00 / 11.00
Median / STD DEV 7.00 / 3.21
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 ActivelyBuy None None
ma100 Buy Buy None
Candlestick PatternDec. 24, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US15117K1034
ceo Dr. David j. d. Sourdive Ph.D.
Website https://www.cellectis.com
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.